KR102037719B1 - Composition for anti-stress agents, antidepressants or anxiolytics including Ionone as active ingredients - Google Patents

Abstract

The present invention relates to an antistress agent, antidepressant or anti-anxiety composition containing ionone as an active ingredient, and more particularly, the present invention relates to an antistress composition comprising depression or an salt thereof as an active ingredient, depression or anxiety disorder. It is to provide a composition for preventing, improving or treating.

Description

Composition for anti-stress agents, antidepressants or anxiolytics including Ionone as active ingredients

The present invention relates to an antistress agent, antidepressant or anti-anxiety composition containing ionone as an active ingredient, and more particularly, the present invention relates to an antistress composition comprising depression or an salt thereof as an active ingredient, depression or anxiety disorder. It is to provide a composition for preventing, improving or treating.

Stress is an adaptive response of the body to internal and external stressors or triggers, and medically, it is defined as a harmful stimulus that promotes the secretion of corticosteroids. The term "stress" began to be used in 1936 when Canadian physiologist Dr. H. Selye published Nature's "Stress Theory."

Stimulus that causes stress is classified into physical, psychological, and physiological stimuli. Physical stimulation refers to temperature, ultraviolet rays, etc. that exist in the natural world, psychological stimulation refers to mental pain, anger, anxiety, tension, and physiological stimulation refers to bacteria, viruses, and allergens. In particular, repeated symptoms such as depression, anxiety, insomnia, and loss of appetite caused by psychological stimulation cause diseases such as depression, anxiety, and sleep disorder.

Depression is a disease that causes deterioration of daily functions by causing various cognitive, mental or physical symptoms due to lowered motivation and depression, and it causes a decline in daily functioning due to deterioration of overall functions such as thought, motivation, motivation, behavior, and sleep. It is difficult and has a high correlation with the prevalence and suicide rate. Anxiety is a mental disorder that usually shows persistent, unrecoverable neurological hypersensitivity, tension, and anxiety over six months, with extreme anxiety in every minor event for no particular reason. Sleep disorders include psychotic symptoms such as self-dissolution, hallucinations, and delusions. Sleep deprivation experiments in rats showed systemic weakness, skin disease, weight loss, increased energy consumption and decreased body temperature. Severe deaths have been reported (Dugovic et al., 1999 High corticosterone levels in prenatally stressed rats predict persistent paradoxical sleep alterations J. Neurosci. 19 (19); 8656-8664).

In case of excessive mental stress, hormones are secreted into the blood through a circulatory system leading to the hypothalamic-pituitary-adrenal axis (HPA axis). The corticotropin releasing factor (CRF) is produced in the hypothalamus of the brain, which binds to the CRF receptor expressed in the pituitary gland and releases adrenocorticotropic hormone (ACTH). . ACTH reaches the adrenal glands through the blood and lymph nodes, promoting the secretion of glucocorticoids such as cortisol, and the glucocorticoids secreted into the blood are delivered to each organ.

Cortisol is a stress hormone of steroid hormones that prepares the body to cope with mental stress by straining the muscles and making the sense organs sensitive. However, when the cortisol hormone is continuously secreted due to repetitive mental stress, the blood concentration of the cortisol is kept constant, causing the body to stay in a tense state and disturb sleep. This, in turn, causes mental stress, causing a vicious cycle of depressive symptoms. Loss of cortisol secretion control function by severe mental stress causes excessive cortisol release, leading to brain atrophy and damage throughout the nervous system, resulting in severe depression and suicide.

In mice overexpressing the CRF gene, symptoms of anxiety and depression are increased and navigational behavior is reduced. It has been implicated in emotional disorders and can cause Cushing syndrome, which causes physical changes such as excessive fat accumulation, muscle atrophy, thin skin and hair loss, and raises plasma levels of corticosteroids (ACTH) and cortisol. Known.

These symptoms are reported to be alleviated by the administration of CRF antagonists (Stenzel-poore et al., 1994). This suggests that the behavior caused by CRF overexpression is mediated by CRF and the CRF receptor. CRF receptors belong to the family of G-protein coupled receptors (GPCRs) in the cell membrane, and when the activity is increased by CRF, the activity of adenylyl cyclase (AC) enzymes underneath is increased to increase cAMP concentration. It is known that related bioreactions occur. On the contrary, when the activity of the CRF receptor is inhibited by the antagonist, it is known that the activity of adenylyl cyclase (AC) underneath is reduced, thereby decreasing the cAMP concentration.

 The early stress recovery diet supplement market was led by St. John's wort (depression, anxiety improvement) and Valerian (sedative, sleep improvement), but the new antistress market has recently expanded rapidly. Material development is required. However, only a few counterparts such as γ-aminobutoryl acid (GABA), theanine and phosphatidyl serine are mentioned, and newly released products are one of the five antistress substances. It is developed by mix | blending the above.

Currently approved antidepressants are drugs that induce a therapeutic effect by suppressing the reabsorption of serotonin released from neuronal ends into pre-synaptic cells, resulting in transient mood swings by increasing blood serotonin concentration and activity. Prozac ™, ingredient fluoxetine, and Celexa ™ ingredient citalopram. However, in the case of such serotonin reuptake inhibitors, only about half of patients show symptomatic improvement and a minimum period of 4 months or more is required, and depending on the patient, there is a problem of continuing to take for 2 to 3 years. In addition, in the case of the serotonin reuptake inhibitor, most of the symptoms are observed within 6 to 12 months when the drug is stopped, and side effects are also known to be serious.

As anti-anxiety drugs, benzodiazepine strains such as diazepam, lorazepam, clonazepam and alprazolam are mainly used, and imidazopyridine such as zolpidem. Drugs of the imidazopyridine family are also used to treat short-term insomnia due to anxiety. However, drugs used for anxiety disorders and mental disorders have a direct effect on the GABA receptors of the central nervous system, which inhibits the central nervous system, resulting in excessive sedation and enhanced central inhibitory effects such as depression, muscle relaxation, and hypnosis. Can be. In addition, drugs that are used for anxiety disorders and mental disorders have a problem that the psychological and physical dependence and the risk of drug abuse is included.

Accordingly, the present inventors have tried to develop a material that is effective in alleviating stress, depressive symptoms or anxiety symptoms in natural products with few side effects. As a result, ionone is an antagonist of the adrenal cortical stimulating hormone releasing factor receptor (CRF receptoe anatagonist). When the ionone and jasmine (jasmine) at the same time used to confirm that the anti-stress, anti-depressant and anti-anxiety effect is significantly increased to complete the present invention.

An object of the present invention is to provide an antistress composition comprising ionone or a salt thereof as an active ingredient.

Still another object of the present invention is to provide a composition for preventing or improving depression or anxiety disorder comprising ionone or a salt thereof as an active ingredient.

Another object of the present invention to provide a pharmaceutical composition for the prevention or treatment of depression or anxiety disorder comprising ionone or a salt thereof as an active ingredient.

The present invention is to solve the above problems, and provides an anti-stress composition comprising ionone or a salt thereof as an active ingredient.

According to one aspect of the present invention, the composition may relieve stress symptoms by inhibiting the activity of the corticosteroid hormone releasing factor.

According to another aspect of the present invention, the composition may relieve stress symptoms by reducing blood corticosterone concentration.

According to another aspect of the present invention, the composition can significantly increase the stress relief effect by further comprising jasmon (jasmone) or salts thereof as an active ingredient.

According to one embodiment of the invention, the composition may be a nutraceutical composition, cosmetic composition or fragrance composition.

The present invention also provides a composition for the prevention or improvement of depression or anxiety disorder comprising ionone (ionone) or a salt thereof as an active ingredient.

According to an aspect of the present invention, the composition may prevent or improve depression or anxiety disorder by inhibiting the activity of the adrenal cortical stimulating hormone releasing factor.

According to another aspect of the present invention, the composition may prevent or ameliorate depression or anxiety disorder by reducing blood corticosterone concentration.

According to another aspect of the present invention, the composition may further increase the effect of preventing or improving depression or anxiety disorder by further comprising jasmone (jasmone) or a salt thereof as an active ingredient.

According to one embodiment of the invention, the composition may be a nutraceutical composition, cosmetic composition or fragrance composition.

In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of depression or anxiety disorder, including ionone (ionone) or a salt thereof as an active ingredient.

According to another aspect of the present invention, the composition may further increase the effect of preventing or treating depression or anxiety disorder by further comprising jasmone (jasmone) or salts thereof as an active ingredient.

Antistress, antidepressant or anti-anxiety compositions comprising ionone of the present invention as an active ingredient may act as an antagonist that inhibits the activity of the adrenal cortical stimulating hormone releasing factor (CRF) and the concentration of glucocorticoids such as corticosteroids in the blood Reducing the symptoms can alleviate the symptoms caused by stress, prevent, ameliorate or treat depression or anxiety disorder. Therefore, the composition of the present invention can be used as antistress, antidepressant or anti-anxiety dietary supplement composition, cosmetic composition, etc., and can be used as an antidepressant, anti-anxiety agent or a wide range of antipsychotics.

Figure 1 shows the concentration of cAMP according to experimental material treatment in HEK293 cells transfected with CRF receptor. Experimental results were measured in three iterations and then expressed as mean and standard error (SEM). Complex) and when treated with CRF alone, were considered significant at p <0.05 (mean ± SEM, * p <0.05, ** p <0.01, *** p <0.001 ).
Figure 2 confirms the tail suspension experiment (A), forced swimming experiment (B) results and plasma corticosterone index change (C) of the mice administered a combination of ionone or ionon and Jasmon complex. The experimental results were expressed as mean and standard error (SEM), and statistical significance using Student's T-test was verified to compare the stress control group with the ionone group, the ionone and jasmine simultaneous group, and was significant at p <0.05. And considered as mean (mean ± SEM, n = 7, * p <0.05, ** p <0.01, *** p <0.001).
Figure 3 shows the corticosteroid concentration of mice fed the experimental diet (including betaionone) in CRF overexpressing mice (mean ± SEM, n = 7, * p <0.05, ** p <0.01, * ** p <0.001).

The inventors have found that the ketone compound ionon acts as an antagonist of corticosteroid-stimulating factor (CRF), reduces blood corticosteroid levels, and improves behavioral indicators of stress, depression or anxiety in animal models. By confirming the point, this invention was completed.

Hereinafter, the present invention will be described in detail.

The present invention provides an antistress composition comprising ionone or a salt thereof as an active ingredient.

Specifically, the ionone is Rubus idaeus (Raspberry), Daucus carota subsp. Sativus (Carrot, Carrot), Prunus It is a fragrance ingredient mainly contained in dulcis (Almond, almond) and Menta (Herb, herb). It is a ketone compound which mainly gives a floral fragrance. The structural formula is C ₁₃ H ₂₀ O and molecular weight is 192.3 g / mol. Ionone includes isomers of alpha-ionone, beta-ionone, and gamma-ionone represented by the following Chemical Formulas 1, 2, and 3, respectively, depending on the molecular structure. Alphaionone is (3E) -4- (2,6,6-trimethylcyclohex-2-en-1-yl) but-3-en-2-one ((3E) -4- (2,6, 6-trimethylcyclohex-2-en-1-yl) but-3-en-2-one), cyclocitrylideneacetone, cycloistrylideneacetone, irisone and jonon are also called. Alphaionone is a pale yellow transparent liquid with melting point of -49 ℃ and boiling point of 126 ~ 128 ℃.

 [Formula 1]

[Formula 2]

[Formula 3]

Ionone is mainly used as a component of shampoos, soaps, cleaning products, body lotions, cosmetics, shower gels, and hair sprays, and is listed as a flavoring agent in the Korean KFDA and US FDA food additive databases, and is mainly used in soft drinks, ice cream, chewing gum, etc. Used. The only report on physiological activity of ionone is that ionon showed strong antimicrobial activity against harmful microorganisms (Findic et al, Synthesis of Terpenoid-Like Bischalcones from α- and β-Ionones and Their Biological Activities, Synthetic Communications, 39: 4362-4374, 2009), but no other biological activity has been reported.

The ionone of the present invention may include an ionone hydrate, an ionone derivative, and the like within the range having the same efficacy as the ionone, and may also include a solvent compound or stereoisomer thereof.

The method for obtaining the ionone is not particularly limited, and may be isolated from the plant containing the ionone, chemically synthesized using a known manufacturing method, or commercially available.

In the present invention, the term “cosmetic acceptable salt”, “food acceptable salt”, “pharmaceutically acceptable salt” or “salt thereof” may be an acid addition salt formed by free acid. have. Acid addition salts can be prepared by conventional methods, for example by dissolving a compound in an excess of aqueous acid solution and precipitating the salt using a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. In addition, equimolar amounts of the compound and acid or alcohol (eg, glycol monomethyl ether) in water can be heated and the mixture can then be evaporated to dryness or the precipitated salts can be suction filtered.

As the free acid, an inorganic acid or an organic acid may be used. Non-limiting examples of the inorganic acid may be hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, and the like, which may be used alone or in combination of two or more. Non-limiting examples of the organic acid are methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid (propionic acid). acid, citric acid, lactic acid, glycolic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid (glucuronic acid), aspartic acid, ascorbic acid, carbonic acid, vanic acid, hydroiodic acid and the like can be used. These may be used alone or in combination of two or more thereof.

In addition, the ionone may use a base to make a cosmetically or food acceptable metal salt. Alkali metal or alkaline earth metal salts can be obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compounds salt, and then evaporating and drying the filtrate. As the metal salt, it is particularly preferable to prepare sodium, potassium or calcium salts, but is not limited thereto. Corresponding silver salts can also be obtained by reacting an alkali or alkaline earth metal salt with a suitable silver salt (eg silver nitrate).

Salts of the ionone may include all salts of acidic or basic groups which may be present in the compound of the ionon, unless otherwise indicated. For example, the salt of the ionon may include sodium, calcium and potassium salts of the hydroxy group, and other cosmetically acceptable salts of the amino group include hardbromide, sulfuric acid, hydrogen sulphate, phosphate, hydrogen phosphate, Dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts, and the like. It can be prepared through the method.

In the present invention, "anti-stress" refers to the relaxation of excessive physical reactions due to internal and external stimulation or to the recovery of mental / physical fatigue. Specifically, the term "antistress" refers to relaxation of tension, relaxation of anxiety or improvement of concentration.

The composition according to the present invention may inhibit the activity of corticotropin releasing factor (CRF).

In one embodiment of the present invention, CRF receptor genes were transfected into HEK293 cells and then treated with CRF material or ionone, and cAMP concentration was measured. As a result, CRF and ionone were treated simultaneously compared to CRF alone. When the concentration of cAMP of the cells was also significantly decreased (-48%), it was found that ionone acts as an antagonist of the CRF receptor (FIG. 1). Anxiety and depression symptoms found in mice overexpressed by the CRF gene have been shown to be alleviated by the administration of CRF antagonists, indicating that the ionon of the present invention is active as an antistress, antidepressant or antianxiety composition.

In addition, the composition according to the present invention can reduce the concentration of corticosterone in the blood.

In one embodiment of the present invention, blood corticosterone concentrations were obtained when dietary supplements containing ionone were ingested in blood corticosteroid concentrations and CRF over-expression mice after stress behavioral indicators in mice intraperitoneally administered with ionone. As a result of confirming that the significant reduction compared to the control group (Fig. 2C, 3), it was found that the ionone of the present invention has activity as an antistress, antidepressant or anti-anxiety composition.

The antistress composition of the present invention may be a health functional food composition, a cosmetic composition or a perfume composition.

In the present invention, the term "health functional food" refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body. Here, 'functional' means to obtain a useful effect for health purposes such as nutrient control or physiological action on the structure and function of the human body. The health functional food of the present invention can be prepared by a method commonly used in the art, and the preparation can be prepared by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the health functional food can also be prepared without limitation as long as the formulation is recognized as a health functional food. The health functional food composition of the present invention has the advantage that there is no side effect that may occur when taking long-term use of the drug, unlike the general medicine, food, and excellent in portability, intake as an adjuvant to enhance the stress relief effect It is possible.

In the anti-stress health functional food according to the present invention, when the ionone is used as an additive of the health functional food, it may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. have. The mixed amount of the active ingredient can be appropriately determined depending on the purpose of use, such as prevention, health or treatment.

Formulations of dietary supplements may be in the form of powders, granules, pills, tablets, capsules, as well as in the form of general foods or beverages.

There is no restriction | limiting in particular in the kind of said food, The foodstuff which can add the said substance is a dairy product including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, etc. , Various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes, etc., may include all foods in a conventional sense.

In general, the ionone may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on 100 parts by weight of the raw material in the manufacture of food or beverage. However, in the case of long-term intake for health and hygiene or for health control, the amount may be below the above range, and the present invention has no problem in terms of safety in terms of using fractions from natural products. The above amount can also be used.

In the functional food according to the present invention, the beverage may contain various flavors or natural carbohydrates and the like as an additional component as a general beverage. The above-mentioned natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate may be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the beverage according to the present invention.

In addition to the above-mentioned anti-stress health functional food according to the present invention, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH regulators, stabilizers, And preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages. In addition, the anti-stress health functional food composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The ratio of such additives is not limited, but is generally selected from 0.01 to 0.1 parts by weight relative to 100 parts by weight of the functional food of the present invention.

As used herein, the term "cosmetic composition" is a composition comprising the compound, the formulation may be in any form. Examples of such formulations include cosmetics prepared using the composition, such as nutrition creams, eye creams, massage creams, creams such as cleansing creams, packs, lotions such as nutrient lotions, essences, soft cosmetics, and nutrient cosmetics. , Powders, foundations, makeup bases, and the like, and may be prepared and commercialized in any of these formulations to achieve the object of the present invention, and are not limited to the above examples. In addition, the cosmetic composition according to the present invention can be formulated by a conventional cosmetic preparation method. Specifically, the cosmetics of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, pack, mask pack, mask sheet It may be one having a formulation selected from the group consisting of, soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, press powder, loose powder and eye shadow.

The cosmetic composition of the present invention may include other additives such as excipients, carriers, etc., in addition to ionone or salts thereof, and it is possible to apply and blend as needed the usual ingredients formulated into general skin cosmetics.

Specifically, the cosmetic composition of the present invention may further include a transdermal penetration enhancer. As used herein, the term transdermal penetration enhancer is a composition that allows a desired component to penetrate into the blood vessel cells of the skin at a high absorption rate. Preferably other phospholipid components, liposome components and the like used in lecithin cosmetics are included, but are not limited to these.

In addition, as the oil which can be mainly used as an oil phase component, one or more selected from vegetable oil, mineral oil, silicone oil and synthetic oil can be used. More specifically, mineral oil, cyclomethicone, squalane, octyldodecyl myristate, olive oil, Vitis binifera seed oil, macadamia nut oil, glyceryl octanoate, castor oil, ethylhexyl isononanoate, dimethicone Chicon, cyclopentasiloxane, sunflower seed oil and the like can be used.

In addition, 0.1 to 5% by weight of a surfactant, a higher alcohol, and the like may be added to reinforce the emulsifying ability. Such surfactants may be used conventional surfactants such as nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, phospholipids, and the like, specifically, sorbitan sesquinolate, polysorbate 60 , Glyceryl stearate, lipophilic glyceryl stearate, sorbitan oleate, sorbitan stearate, die-cetyl phosphate, sorbitan stearate / sucrosecoate, glyceryl stearate / polyethylene glycol-100 Stearate, ceteareth-6 oleate, arachidyl alcohol / behenyl alcohol / arachidyl glucoside, polypropylene glycol-26-butes-26 / polyethylene glycol-40 hydrogenated castor oil, etc. have. As the higher alcohol, alcohols having 12 to 20 carbon atoms, such as cetyl alcohol, stearyl alcohol, octyldodecanol, isostearyl alcohol, etc. may be used alone or in combination of one or more thereof.

The aqueous phase component may further add 0.001 to 5% by weight of one or more thickeners such as carbomer, xanthan gum, bentonite, magnesium aluminum silicate, cellulose gum, dextrin palmitate and the like to adjust the viscosity or hardness of the aqueous phase.

In addition, the cosmetic composition of the present invention, if necessary, active ingredients such as higher fatty acids, vitamins, sunscreens, antioxidants (butylhydroxyanisole, propyl gallic acid, elixolic acid, tocopheryl acetate, butylated hydroxy) Toluene), preservatives (methylparaben, butylparaben, propylparaben, phenoxyethanol, imidazolidinylurea, chlorphenesin, etc.), colorants, pH adjusters (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, Sodium malic acid, fmaric acid, sodium pramate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate, etc., moisturizers (glycerine, sorbitol, propylene glycol, butylene glycol, hexylene glycol, diglycerin , Betaine, glycerin-26, methylgluse-20 and the like), lubricants and the like can be further added.

In addition, the cosmetic composition of the present invention further comprises a substance capable of auxiliaryly providing essential nutrients to the skin, and may preferably contain auxiliary agents including, but not limited to, natural flavors, cosmetic flavors, or herbal medicines. have.

The effective amount of ionone or a cosmetically acceptable salt thereof in the cosmetic composition of the present invention is not particularly limited and may be included in 0.0001 to 20% by weight based on the total weight of the composition. Less than 0.0001% by weight of ionone or its salt in the cosmetics may have a small amount of anti-wrinkle effect, and more than 20% by weight of ionone or its salt may exhibit known toxicity.

The term "fragrance composition" of the present invention may be blended into skin-based bases such as perfumes, cosmetics, bathing agents, foods, pharmaceuticals, and the like, and the blending amount may be appropriately selected to achieve a desired effect according to techniques conventional in the art. It can mix.

The formulation of the fragrance composition of the present invention is not particularly limited, but may be any one selected from powder, granule, liquid spray, solid and gel type formulations.

The fragrance composition includes a cosmetic article including perfume, a soap cleaning article including a bath soap, a room cleaning article including a glass cleaner, a fragrance article including a car air freshener, a bath article containing a herb-type bathing agent, and stationery It can be used to manufacture industrial products including fragrance products, environmental products containing office fragrances or synthetic resin.

Perfume composition of the present invention is based on the total weight of the perfume composition, the active ingredient of the ionon, 0.00001% to 10% by weight, preferably 0.00001% to 10% by weight depending on the product form in which the perfume composition of the present invention is specified 1.0 wt%, more preferably 0.00001 wt% to 0.5 wt%.

Product forms in which the fragrance composition is embodied include soaps, cosmetics, baths, aroma oils, and the like, specifically, body lotions, shampoos, hair rinses, hair conditioners, hair treatments, antiperspirants, skin lotions, skin creams, deodorants , Perfumes (spray or fumigation), lipsticks, lip creams, baths and the like.

These products may contain various additives such as blood circulation promoters, anti-inflammatory agents, humectants, astringents, inorganic salts, organic salts, oily ingredients, surfactants, herbal medicines, pigments, perfumes, sulfur, sinter deposits, fungicides and the like. .

In particular, the fragrance composition of the present invention will generally be used as a skin external preparation of cosmetic formulations, such as makeup products, skin lotions, skin creams, in which case it may contain components commonly used in these cosmetic formulations.

In particular, the fragrance composition of the present invention is preferably used incorporating into a bathing agent in that ionone, the active ingredient, has antistress activity. In this case, the active ingredient may be included in the range of preferably 0.00001 to 1% by weight, more preferably 0.0001 to 0.1% by weight based on the total weight of the bath. When the fragrance composition of the present invention is incorporated into a bath and used, the bath may be added to the bath water at a concentration of 0.015 to 15 ppm.

Bathing agent may contain an inorganic salt, an organic acid, an oily component, etc. in addition to the active ingredient of the fragrance composition of this invention.

Inorganic salts include sodium chloride, sodium bicarbonate, sodium carbonate, borax, sodium sulfate, sodium sulfide, sodium sesquicarbonate, sodium nitrate, sodium thiosulfate, sodium polyphosphate, sodium phosphate, calcium oxide, magnesium oxide, calcium carbonate, magnesium carbonate, potassium chloride, sulfide Potassium and the like, and these may be used alone or as a mixture of two or more thereof. These inorganic salts may be added to the bath at least 5% by weight, preferably at least 10% by weight based on the total weight of the bath.

Examples of the organic acid include succinic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, and the like, which may be used alone or in a mixture of two or more thereof. These organic acids can be added to the bath in the range of 0.1 to 50% by weight, based on the total weight of the bath.

Examples of the oily component include waxes, hydrocarbons, higher fatty acids, higher alcohols, esters, silicone oils, and the like.

The bath may also further contain other ingredients conventionally used in the art. These components include (a) inorganic acids such as boric acid, metasilicic acid, silicic anhydride, (b) medicinal powders such as fennel, ginkgo, ginger, citrus peel, Valerian root, peppermint, ginseng, oats, (c) coal tar dye, Natural pigments identified as harmless to the human body, such as chlorophyll, riboflavin, saffflower, anthraquinone, (d) vitamins such as vitamin A, vitamin C, vitamin D, vitamin E, (e) sulfur, mica powder, clay powder, Ocher powder, rice bran carbide, fungicides, and preservatives.

Such bathing agents can be prepared in any form, such as granules, tablets, solutions, powders and the like.

The present invention also provides a composition for the prevention or improvement of depression or anxiety disorder comprising ionone (ionone) or a salt thereof as an active ingredient.

Details of the ionone are as described above.

As used herein, the term "depression" is a type of mental illness characterized primarily by sadness, tastelessness, loss of feelings, numbness (lack of pleasure), grief, agitation or delay, guilt and worthlessness. Serious cases are accompanied by symptoms such as suicide, hallucinations and delusions.

In addition, the term "anxiety disorder" used in the present invention refers to a case in which excessive psychological pain or severe difficulty in realistic adaptation is caused by pathological anxiety. It is a type of mental illness and is associated with various combinations of psychological and physical “anxiety symptoms” that are not attributable to actual risk but appear as an attack (panic disorder) or persistent state (generalized anxiety disorder). Specifically, anxiety disorders include generalized anxiety disorder, phobia (specific phobias, social phobias, agoraphobia), panic disorders, obsessive-compulsive disorders, and post-traumatic stress disorders ( Post-traumatic stress disorder (PTSD).

Depression and anxiety disorders are the most common mental dysfunction disorders. Depression is primarily a chronic depressive state, most of which is accompanied by sleep disorders, low self-esteem, shame, and suicidal tendencies. Depression is therefore considered a complex disorder, and the mechanisms associated with its pathogenesis are unclear. Anxiety disorders are often mental illnesses manifested by anxious feelings. The main features of anxiety disorders are continuations such as actuation or anxiety, catatonia and fear combined with syndromes such as autonomic nerves disturbance, muscle rigidity, and exercise disturbance. Tense emotions.

(Mineka, S., and R. Zinbarg. 2006. A contemporary learning theory perspective on the etiology of anxiety disorders: it's not what you thought it was.Am Psychol 61: 10-26).

The composition for preventing or improving the depression or anxiety disorder of the present invention may be a nutraceutical composition, cosmetic composition or perfume composition.

Specific contents of the health functional food composition, cosmetic composition or perfume composition are as described above.

In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of depression or anxiety disorder, including ionone (ionone) or a salt thereof as an active ingredient.

Details of the ionone are as described above.

The pharmaceutical composition for preventing or treating depression or anxiety disorder according to the present invention is not particularly limited as long as it contains ionone or a pharmaceutically acceptable salt thereof. Preferably, the dose of ionone may be included in a concentration of 0.1 μM to 1000 μM, but is not limited thereto. At this time, when the ionone is less than the concentration range, there is a problem that it is difficult to effectively prevent or treat the depressive symptoms, anxiety disorder symptoms or related diseases, and when the ionone exceeds the concentration range, including cytotoxicity There may be toxicity concerns.

Pharmaceutical compositions for the prophylaxis or treatment of depression or anxiety disorders according to the present invention are powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterilization, respectively, according to conventional methods. It may be formulated and used in the form of injectable solutions, and may comprise suitable carriers, excipients or diluents commonly used in the manufacture of pharmaceutical compositions for formulation.

The carrier or excipient or diluent may be lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicide, cellulose, methyl cellulose, undetermined. And various compounds or mixtures including vaginal cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like.

When formulated, it may be prepared using diluents or excipients such as fillers, weights, binders, wetting agents, disintegrating agents, and surfactants that are commonly used.

Solid preparations for oral administration may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin and the like in the ionone. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to commonly used simple diluents such as water and liquid paraffin. .

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol gelatin and the like can be used.

Preferred dosages of the pharmaceutical compositions for preventing or treating depression or anxiety disorders according to the present invention vary depending on the patient's condition, weight, degree of disease, drug form, route of administration, and duration, and may be appropriately selected by those skilled in the art. have. However, for the desired effect, it may be administered at 0.0001 to 2,000 mg / kg, preferably at 0.001 to 2,000 mg / kg. Administration may be once a day or may be divided several times. However, the scope of the present invention is not limited by the above dosage.

The pharmaceutical composition for preventing or treating depression or anxiety disorder according to the present invention can be administered to mammals such as rats, mice, livestock, humans by various routes. All modes of administration may be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

The anti-stress composition of the present invention, the composition for preventing or improving depression or anxiety disorder, the pharmaceutical composition for preventing or treating depression or anxiety disorder further comprises a jasmine (jasmone) or salts thereof as an active ingredient to alleviate stress Can significantly increase the effectiveness of preventing, improving or treating depression, anxiety or anxiety disorders.

Specifically, the jasmine is a compound contained in plants such as jasmine and yarrow, the structural formula is C ₁₁ H ₁₆ O, the molecular weight is 164.248 g / mol. Jasmon can be represented by the following formula (1), it is also called cis-jasmone (cis-jasmone).

[Formula 1]

Jasmon is listed as a flavoring agent in the Food and Drug Administration (FDA) and Korea Food and Drug Administration (KFDA) food additive databases and is safe as a food additive in the Joint FAO / WHO Expert Committe on Food Additives (JECFA). Approved.

Jasmon's physiological and general functions have been reported to help calcium absorption. Jasmon has been reported to increase calcium absorption and calcium content of microsomes when treated with microsomes of skeletal muscle in dogs (Antipenko et al., Journal of Biological Chemistry 272.5, 1997). Jasmon's LD ₅₀ value has been reported to be more than 5,000 mg / kg safe for oral administration to rats (Jenner, et al., Food and Cosmetics Toxicology 2 (1964): 327-343.).

Jasmon of the present invention may include a jasmon hydrate, a Jasmon derivative, and the like within the range having the same efficacy as the Jasmon, and may also include a solvent compound or stereoisomer thereof.

The method for obtaining the jasmine is not particularly limited, and may be isolated from a plant containing the jasmine, chemically synthesized using a known manufacturing method, or commercially available.

Below, Through the examples will be described in more detail the present invention. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as limited by these examples.

Example  One. HEK293  Ionon Using Cells CRF  Antagonist Activity Measurement

In order to confirm whether ionone and jasmine act as antagonists of the CRF receptor, transfected with CRF receptor gene in HEK293 cells, the test subjects were treated, and cAMP concentration was measured.

1-1) HEK293  Cell culture and CRF  Receptor Gene Transfection

Specifically, HEK293 cells (American Type Culture Collection, Manassas, VA, USA) were prepared in a 10-well plate in 10% FBS (fetal bovine serum; Gibco, BRL, NY, USA), 1% non-essential amino acids (non 37 ° C. using DMEM (Dulbecco's Modified Eagle's Medium; Hyclone, UT, USA) medium containing essential amino acid) and 1% penicillin / streptomycin, Pen / Strep; Gibco, Grand Island, NY , 5% CO ₂ incubator. Subsequently, serum-free DMEM culture was added to HEK293 cells grown at 70% confluent, and the CRF receptor vector (Origene) was obtained using lipofectamine (lipofectamin 2000; Invitrogen, Massachusetts, USA). , Maryland, USA) was transfected for 24 hours. Subsequently, 20 μM CRF, 1 μM known CRF antagonist (CP 154,526; Sigma, Missouri, USA), 100 μM beta ionone, or beta ionone (100 μM) and Jasmon 100 μM) mixture was treated and further incubated for 24 hours. The beta ionone and jasmon used were purchased from Sigma-Aldrich, Missouri, USA.

1-2) cAMP  Concentration measurement

After 24 hours of treatment with the test substance, the culture medium of the cells in culture was removed, 0.1 M HCl was dispensed at 0.5 ml per well, and left at room temperature for 30 minutes. The mixture was then centrifuged at 600 x g, 10 minutes, 20 conditions, and the supernatant was taken and used for analysis. cAMP activity was measured using a commercial kit (Enzo Life Sciences, NY, USA) and performed according to the manufacturer's protocol.

The results were measured in three repetitions and expressed as mean and standard error.The results were statistically verified using Student's T-test, and the results were statistically significant. Non-jasmon) was compared and treated as being significant at p <0.05 (* p <0.05, ** p <0.01, *** p <0.001).

As a result, as shown in FIG. 1, the cAMP concentration of HEK293 cells was significantly reduced (-61%) when CRF and known CRF antagonists (CP154,526) were treated with CRF alone. In addition, when treated with CRF and beta ionone at the same time, the concentration of cAMP in the cells was also significantly decreased (-48%), compared with only CRF and beta ionone. At the same time, it was confirmed that the reduction was greater (-54%). It was found that beta ionone acts as an antagonist of the CRF receptor and synergistic effect of beta ionone and jasmine together.

Example  2. Ionone in the Mouse Anti-stress , Antidepressive, Anti-anxiety  Check the effect

2-1) Breeding experimental animals and diet

Seven-week-old male C57BL / 6 mice used as experimental animals were supplied from Orient Bio Co., Ltd. (Gyeonggi-do, Korea). The experimental animals were acclimated for one week in the rearing room, and then the control group (CON, n = 6), beta ionone group (IO, n = 6), beta ionone and jasmon group (IO + JA, n = 6). Divided by. Olive oil for the control group, beta-ionone 4 mg / kg body weight for beta-ionone, and beta-ionone and jasmon for 2 mg / kg body weight and 2 mg / kg body weight for olive-ion. One hour before the dissolution of the stress behavioral indicator experiment was dissolved. The beta ionone and jasmon used were purchased from Sigma-Aldrich (Missouri, USA). The experimental animals were kept in a constant space with a temperature of 23 ± 1 ℃ and a humidity of 50 ± 10% and kept for 12 hours in a light and dark cycle. The animals were freely fed Chow (orient bio) and negative water, except for the negative deprivation conducted before sucrose preference experiment. .

2-2) Behavior Indicator Experiment 1: Tail Hanging experiment (tail suspension test, TST )

Tail hanging experiments were performed using the method of Steru et al. (1985). After attaching the fixed device about 1 cm to the tail of the experimental mouse, it is suspended 50 cm from the ground, and the immobilization of the experimental animal using a video tracking system (smart v.2.5.21) The time was measured. When the mouse was suspended and completely stopped without any movement, it was considered as a floating state, and after 2 minutes of adaptation time, the behavioral state was measured for 4 minutes. In general, when stress is induced, anxiety increases and depression increases, resulting in less activity.

As a result, as shown in FIG. 2A, it was confirmed that the dead time was significantly decreased (-37%) in the beta-ionone group (IO) compared to the control group (CON), and when beta-ionone and jasmon were simultaneously administered (IO + JA) it was confirmed that the dead time is significantly reduced (-63%). This resulted in the anti-stress, anti-depressive and anti-anxiety effects of ionone as well as synergistic effects when used simultaneously with Jasmon.

2-3) Behavior Indicator Test 2: Forced swimming test (FST)

Forced swimming experiments were performed using Porsolt et al. (1997). Fill a water tank with a temperature of 25 ± 1 ℃ with 30 cm in a water tank of 40 cm in height and 20 cm in diameter, and then put the mice in the tank one by one and use a video tracking system The immobility time of was measured. The mouse was considered to be floating when the mouse was standing upright with only a face on the water and floating. The state was measured for 4 minutes after 2 minutes of adaptation time. In general, when stress is induced, anxiety increases and depression increases, resulting in less activity.

As a result, it was confirmed that the dead time was significantly reduced (-29%) in the beta ionone group (IO) compared to the control group (CON), and when beta ionone and jasmon were simultaneously administered (IO + JA) This markedly decreased (-72%). Through this, it was found that the ionon not only exhibited antistress, antidepressant and anti-anxiety effects but also synergistic effects when used simultaneously with Jasmon (FIG. 2B).

2-4) plasma Corticosterone ( corticosterone A) concentration measurement

45 minutes after the stress behavioral indicators were over, blood was collected under anesthesia with an avertin. Blood collected from the abdominal aorta was centrifuged at 2000 xg for 15 minutes to separate plasma. Corticosterone concentrations were measured using a commonly used EIA kit (Corticosterone EIA kit; Enzo Life Sciences, NY, USA). Basic experimental methods were performed according to the manufacturer's instructions.

As a result, as shown in FIG. 2C, the plasma corticosterone concentration was significantly decreased (-14%) in the beta ionone group (IO) compared to the control group (CON), and beta ionone and jasmon were simultaneously administered (IO). + JA) the plasma corticosterone concentration was found to be significantly reduced (-35%). Through this, it was found that the ionon not only exhibited antistress, antidepressant and anti-anxiety effects but also synergistic effects when used simultaneously with Jasmon.

Example  3. CRF  Ionone in Overexpressed Mice Anti-stress , Antidepressive, Anti-anxiety  Check the effect

3-1) Experiment Animal Breeding and Experimental Diet

This experiment was conducted for 12 weeks in 28 CRF overexpressing mice (male n = 14, female n = 14) and 14 wild-type mice (male n = 7, female n = 7). Specifically, CRF overexpressing mice received 14 pairs of male and female 7-week-old males and females bred for three generations after wearing CRF overexpressing mice (hemizygous) and wild type mice (littermate) from Jackson lab (Bar Harbor, Maine, USA). It was used for the experiment.

Wild-type mice were fed a normal diet (ND), and CRF overexpressing mice were divided into two groups and ND (n = 14) and beta-ionone supplemented diet (IO) (n = 14), respectively. The diet supplemented with beta ionone had the same composition as ND but contained 0.2% of beta ionone (see Table 1 below). The beta ionone used was purchased from Sigma-Aldrich (Missouri, USA). Experimental animal breeding was carried out in a environment of 12 hours light and dark cycles with a temperature of 23 ± 1 ℃ and a humidity of 50 ± 10%.

Experimental composition table ingredient Normal diet
(g / kg diet) Beta Ionone Supplements
(g / kg diet) Corn starch 397.8 395.8 Casein 200 200 Dextrinized Corn Starch 132 132 Sucrose 100 100 Soybean oil 70 70 cellulose 50 50 Mineral complex 35 35 Vitamin complex 10 10 L-cysteine 3 3 Choline Bitartrate 2.48 2.48 tert-butyhydroquinone 0.01 0.01 Beta ionone - 2 Total (g) 1,000 1,000

During the experiment, the body weight of the test animals was measured at a regular time once a week, and the dietary intake was measured every day.

3-2) Blood Collection and Plasma Corticosterone  Measure

The mice were fasted for 6 hours at the completion of experimental animal breeding, and blood was collected under anesthesia with avertin. Blood collected from the abdominal aorta was centrifuged at 2000 xg for 15 minutes to separate plasma. Corticosterone concentrations were measured using a commonly used EIA kit (Corticosterone EIA kit; Enzo Life Sciences, NY, USA). Basic experimental methods were performed according to the manufacturer's instructions.

As a result, as shown in FIG. 3, the plasma corticosterone of CRF overexpressing mice was significantly increased in both males and females compared to WT mice (male, + 284%; female, + 289%). Plasma corticosterone was significantly reduced in CRF overexpressing mice (male, -32%; female, -26%). From this, beta ionone was found to have an effect of improving the concentration of chronically increased plasma corticosterone.

Hereinafter, a preparation example of a composition containing an extract of the present invention will be described, but the present invention is not intended to be limited thereto but only to be described in detail.

Formulation example  One. Powder  Produce

Ionone 20 mg

Lactose Carb 100 mg

Talc 10 mg

The above ingredients were mixed and filled in an airtight cloth to prepare a powder.

Formulation example  2. Preparation of Tablets

Ionone 10 mg

Corn starch 100 mg

Lactose Carb 100 mg

Magnesium stearate 2mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

Formulation example  3. Manufacture of capsule

Ionone 10 mg

3 mg of microcrystalline cellulose

Lactose carb 14.8 mg

Magnesium Stearate 0.2 mg

After mixing the above components, it was filled in gelatin capsules according to the conventional method for producing a capsule to prepare a capsule.

Formulation example  4. Preparation of Injectables

Ionone 10 mg

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

Monohydrogen phosphate 26 mg

After mixing the above components, it was prepared in the above ingredient content per ampoules (2 mL) according to the conventional method for preparing injections.

Formulation example  5. Liquid  Produce

Ionone 10 mg

Isomerized sugar 10 mg

Mannitol 5 mg

Purified water

Lemon flavor

The above components are dissolved in purified water according to a conventional preparation method, dissolved in purified water, and then lemon juice is added in an appropriate amount, and then adjusted to 100 mL by adding purified water.

Formulation example  6. Functional food  Produce

Ionone 10 mg

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

0.2 μg of vitamin B12

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

Folate 50 ㎍

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium citrate 30 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation example  7. Manufacture of health drinks

Ionone 10 mg

15 g of vitamin C

100 g of vitamin E (powder)

Iron lactate 19.75 g

3.5 g of zinc oxide

Nicotinamide 3.5 g

0.2 g of vitamin A

0.25 g of vitamin B1

0.3 g of vitamin B2

Purified Water Quantification

After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 l container, sealed sterilization and refrigerated and then stored in the present invention Used to prepare healthy beverage compositions.

Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Hereinafter, an example of preparation of a cosmetic composition containing an extract of the present invention will be described, but the present invention is not intended to be limited thereto, but is intended to be described in detail.

Production Example  1. Nutritional Cosmetics ( Milk Croissant )

Ionone 2.0 wt%

Squalane 5.0 wt%

Beeswax 4.0 wt%

Polysorbate60 1.5 wt%

Sorbanthesquioleate 1.5 wt%

0.5% by weight of liquid paraffin

Caprylic / Capric Triglycerides 5.0 wt%

Glycerin 3.0 wt%

Butylene Glycol 3.0 wt%

Propylene Glycol 3.0 wt%

Carboxy vinyl polymer 0.1 wt%

0.2% by weight of triethanolamine

Preservatives, colorings, flavors

Purified water to 100% by weight

Although the above-mentioned compounding ratio is mixed with a component suitable for nutritional longevity in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.

Production Example  2. Softening Cosmetics (Skin Lotion)

Ionone 2.0% by weight

Glycerin 3.0 wt%

Butylene glycol 2.0% by weight

Propylene Glycol 2.0 wt%

Carboxy vinyl polymer 0.1 wt%

PEG 12 nonylphenylether 0.2% by weight

Polysorbate 80 0.4% by weight

Ethanol 10.0 wt%

Triethanolamine 0.1% by weight

Preservatives, colorings, flavors

Purified water to 100% by weight

Although the above-mentioned compounding ratio is mixed and formulated in a preferred embodiment with a component suitable for a relatively softening longevity, the compounding ratio may be arbitrarily modified, and can be prepared according to the manufacturing method in the general cosmetic field.

Production Example  3. Nutrition Cream

Ionone 2.0% by weight

Polysorbate 60 1.5% by weight

Sorbitan sesquioleate 0.5% by weight

PEG60 Cured Castor Oil 2.0% by weight

10% by weight of liquid paraffin

Squalane 5.0 wt%

Caprylic / Capric Triglycerides 5.0 wt%

Glycerin 5.0 wt%

Butylene glycol 3.0% by weight

Propylene Glycol 3.0 Weight%

Triethanolamine 0.2% by weight

Preservative

Pigment amount

Spices

Purified water to 100% by weight

Although the above-mentioned compounding ratio is mixed with a component suitable for nourishing cream in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.

Production Example  4. Massage Cream

Ionone 1.0% by weight

Beeswax 10.0 weight%

Polysorbate 60 1.5% by weight

PEG 60 Cured Castor Oil 2.0% by weight

Sorbanthesquioleate 0.8 wt%

40.0% by weight of liquid paraffin

Squalane 5.0 wt%

Caprylic / Capric Triglyceride 4.0 wt%

Glycerin 5.0 wt%

Butylene glycol 3.0% by weight

Propylene Glycol 3.0 Weight%

Triethanolamine 0.2% by weight

Preservatives, colorings, flavors

Purified water to 100% by weight

Although the above-mentioned compounding ratio is mixed with a component suitable for a massage cream in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.

Production Example  5. Pack

Ionone 1.0% by weight

Polyvinyl alcohol 13.0 wt%

Sodium Carboxymethylcellulose 0.2% by weight

Glycerin 5.0 wt%

Allantoin 0.1 wt%

Ethanol 6.0 wt%

PEG 12 nonylphenyl ether 0.3% by weight

Polysorbate60 0.3 wt%

Preservatives, colorings, flavors

Purified water to 100% by weight

Although the above-mentioned compounding ratio is mixed with a component suitable for a pack in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.

Production Example  6. Gel

Ionone 0.5 wt%

0.05% by weight of ethylenediamine sodium acetate

Glycerin 5.0 wt%

Carboxy vinyl polymer 0.3 wt%

Ethanol 5.0 wt%

PEG 60 Cured Castor Oil 0.5% by weight

0.3% by weight of triethanolamine

Preservatives, colorings, flavors

Purified water to 100% by weight

Although the above-mentioned compounding ratio is mixed with a component suitable for a gel in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.

The compounding ratio is a relatively suitable composition for the cosmetic composition in a preferred embodiment, but can be applied to cosmetics of various uses, including other color cosmetics, according to the efficacy that can be applied to a thin coating on the human body, that is, It can be used for manufacturing as ointment, and the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Hereinafter, an example of preparing a livestock feed composition containing the extract of the present invention will be described, but the present invention is not intended to be limited thereto, but is intended to be described in detail.

Production Example  7. Preparation of Feed Additives

Ionone 0.1 ~ 10%

Tricalcium phosphate 1-20%

Vitamin E 0.01 ~ 0.1%

Enzyme Powder 1 ~ 10%

Lactobacillus 0.1-10%

Glucose 20-90%

Production Example  8. Preparation of feed

The feed additive of Preparation Example 7 was used as an active ingredient to prepare a feed having the following composition.

Feed additive 0.1 ~ 10% of Preparation Example 7

Bran 40-49.9%

Milo 21.20%

Soybean meal 20.00%

Fish Meal 3.00%

Molasses 4.00%

Mineral 1.53%

0.27% vitamin

The foregoing description of the present invention is intended for illustration, and it will be understood by those skilled in the art that the present invention may be easily modified in other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive.

Claims (14)

An antistress composition comprising ionone or a salt thereof as an active ingredient.
The method of claim 1,
The ionone is antistress composition, characterized in that to inhibit the activity of corticotropin releasing factor (CRF).
The method of claim 1,
The ionone is antistress composition, characterized in that to reduce the concentration of corticosterone (corticosterone) in the blood.
The method of claim 1,
The composition is an antistress composition, characterized in that it further comprises jasmon (jasmone) or a salt thereof as an active ingredient.
Functional food composition for antistress comprising ionone or a salt thereof as an active ingredient.
A composition for the prevention or improvement of depression or anxiety disorder comprising ionone or salt thereof as an active ingredient.
The method of claim 6,
The composition is a composition for the prevention or improvement of depression or anxiety disorders, characterized in that it further comprises as an active ingredient (jasmone) or salts thereof.
Functional food composition for the prevention or improvement of depression or anxiety disorder containing ionone (ionone) or salts thereof as an active ingredient.
Pharmaceutical composition for the prevention or treatment of depression or anxiety disorder comprising ionone (ionone) or salts thereof as an active ingredient.
The method of claim 9,
The composition is a pharmaceutical composition for preventing or treating depression or anxiety disorder, characterized in that it further comprises as an active ingredient (jasmone) or a salt thereof.
Cosmetic composition for the prevention or improvement of depression or anxiety disorder containing ionone (ionone) or salts thereof as an active ingredient.
Perfume composition for the prevention or improvement of depression or anxiety disorder containing ionone (ionone) or salts thereof as an active ingredient.
An antistress cosmetic composition comprising ionone or a salt thereof as an active ingredient.
Antistress flavor composition comprising ionone (ionone) or a salt thereof as an active ingredient.

Images